You are here
Ziprasidone Linked to Diabetes
September 1, 2004
FDA and Pfizer notified healthcare professionals of revision to the WARNINGS section of labeling, describing the increased risk of hyperglycemia and diabetes in patients taking Geodon. FDA has asked all manufacturers of atypical antipsychotic medications, including Pfizer, to add this Warning statement to labeling.
To view the warning letters, click here: https://www.fda.gov/safety/medical-product-safety-information/medwatch-safety-alerts-human-medical-products
Source: The Food and Drug Administration
More research is needed to confirm the finding
Study shows "complex genetic risk architecture"
Study says yes, interventions cuts need for meds
Review of 18 studies finds that medium doses have the strongest effects
Research suggests that stress mitigation could be an effective intervention strategy
Children, parents with ADHD benefit from parenting intervention
A new 'road map' might make it easier
First such procedure in the U.S.
Rationing, canceled treatments, and fearful patients